Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.
about
Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerationsObservational data: Understanding the real MS world.Overview of the management of relapsing-remitting multiple sclerosis and practical recommendations.Patient perspectives on switching disease-modifying therapies in the NARCOMS registry.A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.Resource utilization, costs and treatment patterns of switching and discontinuing treatment of MS patients with high relapse activityPersistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosisComparative efficacy of switching to natalizumab in active multiple sclerosis.Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US.Safety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients.Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in Germany.Decision-making in Multiple Sclerosis: The Role of Aversion to Ambiguity for Therapeutic Inertia among Neurologists (DIScUTIR MS).Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life.Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy.Current role of chemotherapy and bone marrow transplantation in multiple sclerosis.Use of Natalizumab in Patients with Multiple Sclerosis: 2015 Update.Considerations on long-term immuno-intervention in the treatment of multiple sclerosis: an expert opinion.Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.The transition from first-line to second-line therapy in multiple sclerosis."No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.Overcoming Therapeutic Inertia in Multiple Sclerosis Care: A Pilot Randomized Trial Applying the Traffic Light System in Medical Education.Use of natalizumab in patients with active relapsing-remitting multiple sclerosis in Kuwait.Predicting PML in natalizumab-treated patients: can we do better?Switching therapies in multiple sclerosis.Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis.Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice.Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.Cost-effectiveness of different strategies for treatment relapsing-remitting multiple sclerosis.Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis.Therapeutic Inertia in the New Landscape of Multiple Sclerosis Care.No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.Therapeutic Inertia in Multiple Sclerosis Care: A Study of Canadian NeurologistsThe Role of Prescribing Generic (Non-proprietary) Drugs in the Prevalence of Therapeutic Inertia in Multiple Sclerosis Care
P2860
Q26752859-72BF4631-50C6-4A33-B4BB-52441E4A2FF5Q30249781-6B1D73F9-AC07-420F-BBA0-88995ECE0CF2Q30993770-61D43A96-4DA7-4C74-94FC-7D0C3D42BA33Q33890415-014D230D-3A01-4E77-82B1-C930CF94517FQ34459729-0D561E97-C57D-420A-BEF2-FDCED771B9D8Q34658763-3A6D592F-2D76-47AC-AD13-FD83A326CC7DQ34737478-41A09B7A-32CB-4041-BB53-00532F294FE8Q35469575-95A11073-90BB-4550-B38C-7D24AAEE2675Q35846504-8B8FDDC3-4845-4F47-B65E-F334DE361DD1Q35884067-1F88E513-DC2B-460E-91F8-CBA0760ECF1CQ36789883-0EB2A90F-6544-4C39-8765-C05DB6726926Q37412487-D60D635B-8750-4881-9F27-7855603BC5CEQ37422818-B1A264F4-E3DD-4B8A-95A8-293883CBAA9EQ37626336-160EC06D-3907-457F-9573-6531440C68B8Q37672368-B91B83BC-5833-4CE8-AEF7-D22CB4FF6377Q37696989-6F21FC40-FBA2-4202-9E66-F7BF30A4B85FQ38163046-2307BBE5-2C5A-4EF3-AA3D-A7E84B1DF024Q38268313-20C446F7-DA7A-4920-B0F3-0D5AD9C31177Q38616689-47047A6E-A171-4ED2-BEB7-634D9849DB68Q38946338-EB1A6CFE-6ED3-4D0E-B6EE-D4755984784DQ39021942-E054342A-AC1D-494C-85C5-731301EBA25BQ41014662-2DC69453-936A-40ED-AE88-233294EE7859Q41185260-9C8752C6-914C-41CA-82BF-C3F26A3DDEC1Q41488417-5926E93F-C7C2-4E3F-81C5-DBA5995CDA99Q42288520-55F2BC7A-9856-4EEA-9151-175EAB1FB1F5Q44495152-65B36EEA-4A15-47A4-8B6D-C8F6E94826B1Q45977173-BFE3B189-8614-4094-AE12-43D98E0E713AQ46870849-B10818D0-D4F5-4FEE-B706-C4BFE867CF5BQ47865523-B963A89D-F039-45C8-A261-397EB1101FE7Q48204088-970131A8-F7CB-4F9E-9D0B-385F2118A5E1Q48858478-2CF132C4-6B8E-484E-B408-D871B031F903Q51167980-50B4D63F-1D47-46FF-B55E-9633D11DF2E0Q52608604-14BF3369-F212-4FA6-B178-7D4464340753Q52641471-600FED20-DB58-4F5C-807F-7D1F5E646026Q57492439-51A59C9A-EF49-4A00-ABD6-62C8DD4B0721Q58122615-994A1751-FC87-427B-93C5-F69CF95A86F3
P2860
Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Escalation to natalizumab or s ...... relapsing multiple sclerosis.
@en
Escalation to natalizumab or s ...... relapsing multiple sclerosis.
@nl
type
label
Escalation to natalizumab or s ...... relapsing multiple sclerosis.
@en
Escalation to natalizumab or s ...... relapsing multiple sclerosis.
@nl
prefLabel
Escalation to natalizumab or s ...... relapsing multiple sclerosis.
@en
Escalation to natalizumab or s ...... relapsing multiple sclerosis.
@nl
P2093
P2860
P356
P1476
Escalation to natalizumab or s ...... relapsing multiple sclerosis.
@en
P2093
Carlo Pozzilli
Claudio Gasperini
Costanza Giannì
Giovanna Borriello
Laura De Giglio
Laura Leonardi
Luca Prosperini
Simonetta Galgani
P2860
P356
10.1177/1352458511417481
P577
2011-08-09T00:00:00Z